Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Researchers in the USA have found that an immunotherapy drug is more effective at treating people with advanced lung cancer than standard chemotherapy drugs.
The study, published in The Lancet, involved more than 1,000 participants with a certain type of non-small cell lung cancer who had previously received treatment for their condition.
Participants were randomly selected to receive a course of the immunotherapy drug, pembrolizumab, or docetaxel, the standard chemotherapy drug.
The researchers found that the people who were treated with immunotherapy lived longer than those who were given chemotherapy, and that their tumours were more likely to shrink by a significant amount.
This finding could offer new hope for lung cancer treatment that avoids the toxicity associated with chemotherapy.
Pembrolizumab was licensed for use by the European Medicines Agency for the treatment of skin cancer in July. It is not currently licensed for the treatment of lung cancer.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79